Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Reports on the association between sarcopenic visceral obesity and nonalcoholic fatty liver disease (NAFLD)-associated morbidities remain scarce. We investigated the association between sarcopenia and visceral obesity, and the influence of this association on hepatic and coronary comorbidities. Methods: The appendicular skeletal muscle mass to visceral fat area ratio (SV ratio) was evaluated using bioelectric impedance analysis. NAFLD and significant liver fibrosis were assessed using transient elastography, and high atherosclerotic cardiovascular disease (ASCVD) risk was defined as a 10-year ASCVD risk score >10%. Sarcopenia was defined as appendicular skeletal muscle mass adjusted by body mass index (<0.789 for men and <0.512 for women). Results: In total, 82.0% (n=1,205) of the entire study population had NAFLD, and 14.6% of these individuals (n=176) exhibited significant liver fibrosis. Individuals with the lowest SV ratio had a significantly increased risk of NAFLD, significant liver fibrosis, and high ASCVD risk (all p<0.05). Individuals with both the lowest SV ratio and sarcopenia had the highest risk of developing NAFLD (odds ratio [OR]=3.11), significant liver fibrosis (OR=2.03), and high ASCVD risk (OR=4.15), compared with those with a higher SV ratio and without sarcopenia (all p<0.05). Conclusions: Low SV ratio combined with sarcopenia was significantly associated with an increased risk of NAFLD, significant liver fibrosis, and high ASCVD risk among individuals with a high risk of NAFLD.
Abstract
Background/Aims: Reports on the association between sarcopenic visceral obesity and nonalcoholic fatty liver disease (NAFLD)-associated morbidities remain scarce. We investigated the association between sarcopenia and visceral obesity, and the influence of this association on hepatic and coronary comorbidities. Methods: The appendicular skeletal muscle mass to visceral fat area ratio (SV ratio) was evaluated using bioelectric impedance analysis. NAFLD and significant liver fibrosis were assessed using transient elastography, and high atherosclerotic cardiovascular disease (ASCVD) risk was defined as a 10-year ASCVD risk score >10%. Sarcopenia was defined as appendicular skeletal muscle mass adjusted by body mass index (<0.789 for men and <0.512 for women). Results: In total, 82.0% (n=1,205) of the entire study population had NAFLD, and 14.6% of these individuals (n=176) exhibited significant liver fibrosis. Individuals with the lowest SV ratio had a significantly increased risk of NAFLD, significant liver fibrosis, and high ASCVD risk (all p<0.05). Individuals with both the lowest SV ratio and sarcopenia had the highest risk of developing NAFLD (odds ratio [OR]=3.11), significant liver fibrosis (OR=2.03), and high ASCVD risk (OR=4.15), compared with those with a higher SV ratio and without sarcopenia (all p<0.05). Conclusions: Low SV ratio combined with sarcopenia was significantly associated with an increased risk of NAFLD, significant liver fibrosis, and high ASCVD risk among individuals with a high risk of NAFLD.
참고문헌 (32)
- Cruz-Jentoft AJ, "Sarcopenia", Lancet, 393, pp.2636~2646 (2019)
- Cruz-Jentoft AJ, "Sarcopenia : revised European consensus on definition and diagnosis", Age Ageing, 48, pp.16~31 (2019)
- Petermann-Rocha F, "Global prevalence of sarcopenia and severe sarcopenia : a systematic review and meta-analysis", J Cachexia Sarcopenia Muscle, 13, pp.86~99 (2022)
- Ethgen O, "The future prevalence of sarcopenia in Europe : a claim for public health action", Calcif Tissue Int, 100, pp.229~234 (2017)
- Batsis JA, "Sarcopenic obesity in older adults : aetiology, epidemiology and treatment strategies", Nat Rev Endocrinol, 14, pp.513~537 (2018)
- Han E, "Sarcopenia is associated with albuminuria independently of hypertension and diabetes : KNHANES 2008-2011", Metabolism, 65, pp.1531~1540 (2016)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Chitturi S, "The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2 : management and special groups", J Gastroenterol Hepatol, 33, pp.86~98 (2018)
- Tang AS, "Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke : an updated meta-analysis with 135, 602 individuals", Clin Mol Hepatol, 28, pp.483~496 (2022)
- Han E, "Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk", Am J Gastroenterol, 115, pp.584~595 (2020)
- Huang DQ, "Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 18, pp.223~238 (2021)
- Shin HS, "Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases", Clin Mol Hepatol, 28, pp.773~789 (2022)
- Kim TN, "Skeletal muscle mass to visceral fat area ratio is associated with metabolic syndrome and arterial stiffness : the Korean Sarcopenic Obesity Study(KSOS)", Diabetes Res Clin Pract, 93, pp.285~291 (2011)
- Luo X, "The prevalence rate of adult sarcopenic obesity and correlation of appendicular skeletal muscle mass index with body mass index, percent body fat, waist-hip ratio, basal metabolic rate, and visceral fat area", Metab Syndr Relat Disord, 21, pp.48~56 (2023)
- Cho Y, "Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex", Hepatol Commun, 6, pp.2238~2252 (2022)
- Kim Y, "Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease", Gut Liver, 16, pp.290~299 (2022)
- Song W, "Association between sarcopenic obesity status and nonalcoholic fatty liver disease and fibrosis", Gut Liver, 17, pp.130~138 (2023)
- Sasso M, "Controlled attenuation parameter(CAP) : a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis : preliminary study and validation in a cohort of patients with chronic liver disease from various causes", Ultrasound Med Biol, 36, pp.1825~1835 (2010)
- Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
- Soon G, "Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease : histological perspective", Clin Mol Hepatol, 27, pp.44~57 (2021)
- Zhang X, "Application of transient elastography in nonalcoholic fatty liver disease", Clin Mol Hepatol, 26, pp.128~141 (2020)
- Han E, "Albuminuria is associated with steatosis burden in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease", Diabetes Metab J, 45, pp.698~707 (2021)
- Heo JY, "Combination of transient elastography and an enhanced liver fibrosis test to assess the degree of liver fibrosis in patients with chronic hepatitis B", Gut Liver, 12, pp.190~200 (2018)
- Ling CH, "Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population", Clin Nutr, 30, pp.610~615 (2011)
- Studenski SA, "The FNIH sarcopenia project : rationale, study description, conference recommendations, and final estimates", J Gerontol A Biol Sci Med Sci, 69, pp.547~558 (2014)
- Janssen I, "Low relative skeletal muscle mass(sarcopenia)in older persons is associated with functional impairment and physical disability", J Am Geriatr Soc, 50, pp.889~896 (2002)
- Goff DC Jr, "2013 ACC", AHA guideline on the assessment of cardiovascular risk : a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
- Kim TH, "Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis", Clin Mol Hepatol, 28, pp.876~889 (2022)
- Kohara K, "Arterial stiffness in sarcopenic visceral obesity in the elderly : JSHIPP study", Int J Cardiol, 158, pp.146~148 (2012)
- Yamashita M, "Prognostic value of sarcopenic obesity estimated by computed tomography in patients with cardiovascular disease and undergoing surgery", J Cardiol, 74, pp.273~278 (2019)
- Fukuda T, "Sarcopenic obesity assessed using dual energy X-ray absorptiometry(DXA)can predict cardiovascular disease in patients with type 2 diabetes : a retrospective observational study", Cardiovasc Diabetol, 17, pp.55~ (2018)
- Chia YC, "Validation of the pooled cohort risk score in an Asian population : a retrospective cohort study", BMC Cardiovasc Disord, 14, pp.163~ (2014)